Diabetes Center of Excellence, Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio, Lackland, TX 78236, United States.
Endocrinology Service, San Antonio Military Medical Center, Joint Base San Antonio, Ft. Sam Houston, TX 78234, United States.
Patient Educ Couns. 2018 Aug;101(8):1490-1495. doi: 10.1016/j.pec.2018.03.001. Epub 2018 Mar 7.
We hypothesized that diabetes-related distress would vary by type of diabetes and medication regimen [Type 1 diabetes (T1DM), Type 2 diabetes with insulin use (T2DM-i), Type 2 diabetes without insulin use (T2DM)]. Thus, the aim of this study was to identify groups with elevated diabetes-related distress.
We administered the 17-item Diabetes-related Distress Scale (DDS-17) to 585 patients. We collected demographics, medications, and lab results from patient records.
Patients were categorized by type of diabetes and medication: T1DM (n = 149); T2DM-i (n = 333); and T2DM (n = 103). ANOVA revealed significant differences in sample characteristics. ANCOVA were conducted on all four DDS-17 domains [Emotional Burden (EB); Physician-related Distress (PD); Regimen-related Distress (RD); and Interpersonal Distress (ID)]; covariates included in the models were sex, age, duration of diabetes, BMI, and HbA1c. EB was significantly lower in T1DM than T2DM-i, p < 0.05. In addition, RD was significantly lower in T1DM than either T2DM-i, p < 0.05 and T2DM, p < 0.05.
EB and RD are higher for those with type 2 diabetes. Thus, interventions to reduce EB and RD need to be considered for patients with type 2 diabetes.
DDS-17 is useful in identifying diabetes-related distress in patients with diabetes. Efforts need to be made to reduce EB and RD.
我们假设糖尿病相关的困扰会因糖尿病的类型和药物治疗方案而有所不同[1 型糖尿病（T1DM）、使用胰岛素的 2 型糖尿病（T2DM-i）、不使用胰岛素的 2 型糖尿病（T2DM）]。因此，本研究的目的是确定具有较高糖尿病相关困扰的群体。
我们向 585 名患者发放了 17 项糖尿病相关困扰量表（DDS-17）。我们从患者记录中收集了人口统计学资料、药物和实验室结果。
患者根据糖尿病类型和药物治疗方案进行分类：T1DM（n=149）；T2DM-i（n=333）；T2DM（n=103）。方差分析显示样本特征存在显著差异。对所有四个 DDS-17 领域[情绪负担（EB）；与医生相关的困扰（PD）；治疗方案相关的困扰（RD）；以及人际困扰（ID）]进行了协方差分析；模型中的协变量包括性别、年龄、糖尿病病程、BMI 和 HbA1c。与 T2DM-i 相比，T1DM 的 EB 显著降低，p<0.05。此外，与 T2DM-i 和 T2DM 相比，T1DM 的 RD 显著降低，p<0.05。
EB 和 RD 在 2 型糖尿病患者中更高。因此，需要考虑针对 2 型糖尿病患者的干预措施来降低 EB 和 RD。
DDS-17 可用于识别糖尿病患者的糖尿病相关困扰。需要努力降低 EB 和 RD。
